Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)

Hematological Oncology - United Kingdom
doi 10.1002/hon.41_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Augment: Relapsed/Refractory Indolent NHL Patients Were More Sensitive to Next Treatment Following Lenalidomide/Rituximab (R2 ) Than Rituximab/Placebo

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Augment Phase Iii Study: Lenalidomide/Rituximab (R2 ) Improved Efficacy Over Rituximab/Placebo in Relapsed/Refractory Follicular Patients Irrespective of Pod24 Status

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Phase Iiib Study of Lenalidomide Plus Rituximab Followed by Maintenance in Relapsed or Refractory Nhl: Analysis of Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2 ) VERSUS R PLUS PLACEBO

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Copanlisib Treatment of Patients With Relapsed or Refractory Marginal Zone Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rituximab Alone (R) Versus Rituximab Plus Bendamustine (Br) for Splenic (Smzl) and Nodal Marginal Zone Lymphoma (Nmzl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma

American Journal of Hematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy